Insight

$Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma$

Jul 3, 2024, 02:35

Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma

Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X:

“Absolutely abscopal responses …. in myeloma??

Fascinating small Ph2 trial in The Lancet Haematology by Khan Sagar Lonial et al:

Pembro q3wk + 1 Fx RT to EMD sites… 7/25 responders, inc. 2 CRs. Better than I might’ve guessed for pembro monoTx in multiple myeloma.”

$Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma$

Read further.
Source: Rahul Banerjee/X

abscopal responses Assistant professor cancer complete response EMD sites immunotherapy Khan Sagar Lonial multiple myeloma Myeloma OncoDaily Oncology oncology research pembrolizumab phase 2 trial radiotherapy Rahul Banerjee The Lancet Haematology UW Medicine

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage